Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
558 results about "High avidity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anti-mesothelin antibodies having high binding affinity
InactiveUS7081518B1Peptide/protein ingredientsHybrid cell preparationAnti-Mesothelin AntibodyAntiendomysial antibodies
Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.
Owner:UNITED STATES OF AMERICA
Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ActiveCN101213297AMicrobiological testing/measurementImmunoglobulins against cell receptors/antigens/surface-determinantsImmunotherapeutic agentProgrammed death
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Owner:ONO PHARMA CO LTD +1
Soluble divalent and multivalent heterodimeric analogs of proteins
InactiveUS20020127231A1Well representedHigh affinityVirusesPeptide/protein ingredientsADAMTS ProteinsSpecific immunity
Specificity in immune responses is in part controlled by the selective interaction of T cell receptors with their cognate ligands, peptide / MHC molecules. The discriminating nature of this interaction makes these molecules, in soluble form, good candidates for selectively regulating immune responses. Attempts to exploit soluble analogs of these proteins has been hampered by the intrinsic low avidity of these molecules for their ligands. To increase the avidity of soluble analogs for their cognates to biologically relevant levels, divalent peptide / MHC complexes or T cell receptors (superdimers) were constructed. Using a recombinant DNA strategy, DNA encoding either the MHC class II / peptide or TCR heterodimers was ligated to DNA coding for murine Ig heavy and light chains. These constructs were subsequently expressed in a baculovirus expression system. Enzyme-linked immunosorbant assays (ELISA) specific for the Ig and polymorphic determinants of either the TCR or MHC fraction of the molecule indicated that infected insect cells secreted approximately 1 .mu.g / ml of soluble, conformnationally intact chimeric superdimers. SDS PAGE gel analysis of purified protein showed that expected molecular weight species. The results of flow cytometry demonstrated that the TCR and class II chimeras bound specifically with high avidity to cells bearing their cognate receptors. These superdimers will be useful for studying TCR / MHC interactions, lymphocyte tracking, identifying new antigens, and have possible uses as specific regulators of immune responses.
Owner:SCHNECK JONATHAN +1
Anti-VEGF antibodies
ActiveUS7758859B2Senses disorderImmunoglobulins against growth factorsAnti vegf antibodyBacteriophage
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
Owner:GENENTECH INC
High avidity polyvalent and polyspecific reagents
InactiveUS20080152586A1In-vivo radioactive preparationsImmunoglobulins against animals/humansEGF-like domainImaging agent
This invention provides polyvalent or polyspecific protein complexes, comprising three or more polypeptides which associate to form three or more functional target-binding regions (TBRs), and in which each individual polypeptide comprises two or more immunoglobulin-like domains which are covalently joined together, such that two Ig-like domains in a single polypeptide do not associate with each other to form a TBR. By using a linker peptide of fewer than three amino acid residues the immunoglobulin-like domains of the individual polypeptides are prevented from associating, so that complex formation between polypeptides is favoured. Preferably the polyvalent or polyspecific protein is a trimer or tetramer. The proteins of the invention have specificities which may be the same or different, and are suitable for use as therapeutic, diagnostic or imaging agents.
Owner:AVIPEP
Immunonanotherapeutics that Provide IgG Humoral Response Without T-Cell Antigen
ActiveUS20100183727A1Improve responseSsRNA viruses negative-senseAntibacterial agentsNanocarriersImmune therapy
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
Owner:MASSACHUSETTS INST OF TECH +2
Antibody pair screening methods
The invention provides methods for identifying antibody preparations that can form a pair of antibodies that optimally detect a target antigen, for example, in a sandwich immunoassay. These methods provide high affinity and epitope-specific antibodies.
Owner:KIMBERLY-CLARK WORLDWIDE INC
Human antibodies that bind human il-12 and methods for producing
InactiveUS20080305114A1Avoid interferencePreservationNervous disorderPeptide/protein ingredientsDiseaseAntigen binding
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Owner:ABBVIE DEUTSHLAND GMBH & CO KG
Methods of preventing and treating RSV infections and related conditions
InactiveUS20060115485A1High affinityEfficient reductionAntibacterial agentsSenses disorderAntigenHalf-life
The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2×105 M−1s−1 and a dissociation rate (koff) of less than 5×10−4 s−1.
Owner:MEDIMMUNE LLC
Ultra high affinity neutralizing antibodies
InactiveUS7740851B2Low costReduce efficacyHybrid immunoglobulinsAntibody mimetics/scaffoldsDiseaseComplementarity determining region
Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.
Owner:MEDIMMUNE LLC
High affinity anti-TNF-alpha antibodies and method
InactiveUS20060024308A1Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntigen bindingAnti tnf alpha
An isolated human anti-TNF-α antibody, or antigen-binding portion thereof, containing at least one high-affinity VL or VH antibody chain that is effective, when substituted for the corresponding VL or VH chain of the anti-TNF-α scFv antibody having sequence SEQ ID NO: 1, to bind to human TNF-α with a Koff rate constant that is at least 1.5 fold lower than that of the antibody having SEQ ID NO: 1, when determined under identical conditions.
Owner:BIOREN
IL-12/p40 binding proteins
The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and / or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and / or hIL-23 and neutralize h IL-12 and / or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and / or hIL-23 and for inhibiting hIL-12 and / or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and / or hIL-23 activity is detrimental.
Owner:ABBVIE INC
Selective high affinity polydentate ligands and methods of making such
ActiveUS20060084115A1Easy to addImprove stabilityOrganic active ingredientsBiocideHigh selectivityHigh avidity
This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
Owner:RGT UNIV OF CALIFORNIA
Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
This invention relates to the use of oligourea molecules to specifically inhibit protein-nucleic acid interactions. In particular, it provides an oligourea molecule that competes with the Tat molecule for the TAR RNA of HIV-1. Also provided is a method specifically inhibiting protein-nucleic and interactions, and kits.
Owner:WISCONSIN ALUMNI RES FOUND +1
Engineering t cell receptors
InactiveUS20150191524A1Immunoglobulin superfamilySugar derivativesMajor histocompatibilityPeptide ligand
The use of model T cell receptors (TCRs) as scaffolds for in vitro engineering of novel specificities is provided. TCRs with de novo binding to a specific peptide-major histocompatibility complex (MHC) product can be isolated by: 1) mutagenizing a T cell receptor protein coding sequence to generate a variegated population of mutants (a library), 2) selection of the library of TCR mutants with the specific peptide-MHC, using a process of directed evolution and a “display” methodology (e.g., yeast, phage, mammalian cell) and the peptide-MHC ligand. The process can be repeated to identify TCR variants with improved affinity for the selecting peptide-MHC ligand.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Methods of preventing and treating rsv infections and related conditions
The present invention provides methods for preventing, managing, treating and / or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and / or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and / or LRI), and / or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and / or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and / or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2×105 M−1s−1 and a dissociation rate (koff) of less than 5×10−4 s−1.
Owner:MEDIMMUNE LLC
IMMUNONANOTHERAPEUTICS THAT PROVIDE IgG HUMORAL RESPONSE WITHOUT T-CELL ANTIGEN
ActiveUS20120087890A1Improve responseEffective amountSsRNA viruses negative-senseAntibacterial agentsNanocarriersAntibody production
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising such nanocarriers. The present invention provides methods of designing, manufacturing maceutical compositions thereof.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +2
Full-human huTIGIT monoclonal antibody and application thereof
The invention relates to an anti-human TIGIT monoclonal antibody which is particularly related to high-affinity anti-human TIGIT monoclonal antibody with blocking activity. A large-capacity fully-synthetic human phage antibody library is constructed, the specific anti-human TIGIT monoclonal antibody and the high-affinity anti-human TIGIT monoclonal antibody which is optimized after molecular evolution are screened from the human phage antibody library, and the monoclonal antibody comprises a full-human frame region and variable regions of a full-human light chain and a heavy chain.
Owner:ANHUI ANKE BIOTECHNOLOGY (GRP) CO LTD
Fibrinogen binding moieties
ActiveUS7041790B2Increased serum half-lifeExtended half-lifeFibrinogenMammal material medical ingredientsBinding peptideFibrinogen binding
Compositions comprising non-naturally occurring fibrinogen binding moieties are described, together with methods of use thereof, e.g., for detecting or isolating fibrinogen molecules in a solution, for blood circulation imaging, and for linking therapeutics or other molecules to fibrinogen. Preferred binding peptides having a high affinity for fibrinogen are particularly disclosed.
Owner:TAKEDA PHARMA CO LTD
High affinity human antibodies to tumor antigens
This invention provides for novel human antibodies that specifically bind to c-erbB-2. The antibodies may be used alone or as components of chimeric molecules that specifically target and deliver effector molecules to cells overexpressing c-erbB-2.
Owner:RGT UNIV OF CALIFORNIA
Aptamer-based Sandwich ELASA method for detecting nervous necrosis virus infection of groupers
InactiveCN105785023AFast specificityThe detection process is fastBiological testingTrue positive rateHorse radish peroxidase
The invention discloses an aptamer-based Sandwich ELASA method for detecting nervous necrosis virus infection of groupers. The method comprises the following steps: fixing a biotin-labeled aptamer onto a pore plate pre-coated with streptavidin; capturing CP proteins in a to-be-detected sample by the fixed aptamer, and combining the CP proteins by the biotin-labeled aptamer; adding horse radish peroxidase-streptavidin for incubating and combining, developing by a horse radish peroxidase developing kit, and analyzing whether NNV virus infection exists according to light absorption value change. According to the invention, by utilizing the characteristics of high affinity and high specificity of the aptamer, a Sandwich ELASA detection method based on aptamer detection is established and can be used for detecting nervous necrosis viruses during grouper culture. Compared with the traditional ELISA and other detection methods, the method disclosed by the invention has the characteristics of high detection speed, high sensitivity and specificity, low cost and high simplicity in operation.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY - CHINESE ACAD OF SCI
Humanized monoclonal antibody and application thereof
ActiveCN107586335AStrong neutralizing activityImmunoglobulins against virusesAntiviralsBaculovirus expressionHumanized antibody
The present invention discloses a humanized monoclonal antibody and an application thereof, belonging to the technical field of medicine. In the invention, the humanized transformation is carried outon a rat monoclonal antibody 2A10G6, the rat monoclonal antibody 2A10G6 is expressed by baculovirus, and the humanized antibody h2A10G6 is obtained. The h2A10G6 antibody of the present invention has high affinity and neutralization activity against yellow fever virus, dengue fever and West Nile virus, and can be applied to clinical treatment and prevention of yellow fever virus, dengue virus and West Nile virus.
Owner:INST OF MICROBIOLOGY - CHINESE ACAD OF SCI +1
High affinity humanized anit-cea monoclonal antibodies
InactiveUS20020052479A1Reduce and potentially eliminate elicitingLow immunogenicityAnimal cellsIn-vivo radioactive preparationsCancer cellIn vivo
Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
Owner:THE DOW CHEM CO
High affinity Siglec ligands
The invention relates to high affinity Siglec ligands that are useful for isolating cells that express Siglecs and for delivering agents to cells that express Siglecs. In one embodiment, the invention provides a method for treating cancer in a mammal that involves administering a Siglec ligand of the invention to the mammal, where the Siglec ligand is linked to a therapeutic agent.
Owner:PAULSON JAMES
Selective high-affinity polydentate ligands and methods of making such
ActiveUS9884070B2Easy to addImprove stabilityBiocideOrganic active ingredientsHigh selectivityAvidity
This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
Owner:RGT UNIV OF CALIFORNIA
Anti-VEGF antibodies
Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naive libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
Owner:GENENTECH INC
Isolation of binding proteins with high affinity to ligands
The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating binding proteins capable of binding small molecules and peptides via “display-less” library screening. In the technique, libraries of candidate binding proteins, such as antibody sequences, are expressed in soluble form in the periplasmic space of gram negative bacteria, such as Escherichia coli, and are mixed with a labeled ligand. In clones expressing recombinant polypeptides with affinity for the ligand, the concentration of the labeled ligand bound to the binding protein is increased and allows the cells to be isolated from the rest of the library. Where fluorescent labeling of the target ligand is used, cells may be isolated by fluorescence activated cell sorting (FACS). The approach is more rapid than prior art methods and avoids problems associated with the surface-expression of ligand fusion proteins employed with phage display.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Recombinant fusion proteins with high affinity binding to gold and applications thereof
InactiveUS20050106625A1Solve the complicated productionEasy to purifySugar derivativesPeptide/protein ingredientsBinding peptideBound property
The present invention provides a method to firmly attach any polypeptide to a gold surface regardless of its intrinsic gold-binding properties. The method describes the production of recombinant fusion proteins consisting of polypeptides of interest and a high affinity gold binding peptide consisting of 1 to 7 repeats of a unique amino acid sequence. By this method, many biologically active polypeptides lacking intrinsic gold-binding properties can be firmly attached to gold surfaces. The disclosure includes evidence that fusion proteins containing the gold-binding sequences provide superior stability and activity compared to similar molecules lacking the tag when used to construct biosensors. The invention provides a method that is a significant improvement over existing chemical and physical adsorption protocols to attach polypeptides to gold and, therefore, can provide benefits to many applications utilizing gold.
Owner:BIOHESION
Anit-il-23 antibiodies
InactiveCN101248088ANervous disorderImmunoglobulins against cytokines/lymphokines/interferonsDiseaseAutoimmune disease
The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.Owner:ELI LILLY & CO
Single-domain antigen-binding antibody fragments derived from llama antibodies
InactiveUS20060246058A1Increase probabilityOvercome limitationsPeptide librariesMicrobiological testing/measurementComplementarity determining regionAntigen Binding Fragment
A phage display library of variable heavy domain (VHH or VH) fragments (sdAb fragments) derived from the antibody repertoire of a non-immunized llama is disclosed. The sdAb fragments of the library are characterized by the absence of cysteine residues in complementarity determining regions (CDRs) and a very low presence of residues of glutamic acid, arginine and glycine at positions 44, 45 and 47, respectively, of the VL interface of the variable heavy domain VHH. The large size of the library (in the order of 109) makes it a source of antigen-binding fragments having high affinity to almost any antigen of interest. The library is preferably generated using a modified fd-tet phage growing in plaques in the absence of a tetracycline.
Owner:NAT RES COUNCIL OF CANADA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap